{"id":"W2118779298","doi":"10.1016/s1470-2045(15)70081-1","title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":333,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Université de Montréal; University of Colorado Denver; Leids Universitair Medisch Centrum; Centre Léon Bérard; Università degli Studi di Padova; Università Cattolica del Sacro Cuore; Erasmus Medisch Centrum; Astellas Pharma; University of Miami","keywords":"Medicine; Tolerability; Adrenocortical carcinoma; Clinical endpoint; Placebo; Internal medicine; Population; Oncology; Carcinoma; Clinical trial; Adverse effect; Surgery; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1504030667974675,"score_gpt":0.411612096007158,"score_spread":0.2612090292096905,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}